In yesterday’s Wall Street session, Geron Corp (NASDAQ:GERN) shares traded at $3.40, up 1.49% from the previous session.
GERN stock price is now -13.60% away from the 50-day moving average and -17.25% away from the 200-day moving average. The market capitalization of the company currently stands at $2.09B.
With the price target of $8, H.C. Wainwright recently initiated with Buy rating for Geron Corp (NASDAQ: GERN). , while ‘Leerink Partners’ rates the stock as ‘Outperform’
In other news, GRETHLEIN ANDREW J, EVP, Chief Operating Officer sold 674,348 shares of the company’s stock on Jul 08 ’24. The stock was sold for $3,073,004 at an average price of $4.56. Upon completion of the transaction, the EVP, Chief Operating Officer now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 10 ’24, EVP, Chief Medical Officer Feller Faye sold 287,900 shares of the business’s stock. A total of $1,334,129 was realized by selling the stock at an average price of $4.63. A total of 6.59% of the company’s stock is owned by insiders.
During the past 12 months, Geron Corp has had a low of $1.64 and a high of $5.34. As of last week, the company has a debt-to-equity ratio of 0.30, a current ratio of 2.89, and a quick ratio of 2.74. The fifty day moving average price for GERN is $3.9352 and a two-hundred day moving average price translates $4.1087 for the stock.
The latest earnings results from Geron Corp (NASDAQ: GERN) was released for 2024-09-30. The net profit margin was -682.48% and return on equity was -69.03% for GERN. The company reported revenue of $28.27 million for the quarter, compared to $0.16 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 17138.41 percent.
